on Xlife Sciences AG (isin : CH0461929603)
Xlife Sciences Unveils Award-Winning Liver PET Tracer
Xlife Sciences AG has announced a significant achievement with DAZAmed, the first liver-specific PET tracer. Developed in collaboration with x-nuclear diagnostics GmbH, inflamed pharma GmbH, and Jena University Hospital, DAZAmed secured the top spot in the 2025 Lothar Späth Award. This recognition highlights its scientific and commercial potential.
The tracer marks a breakthrough in nuclear medicine by enabling precise imaging of liver diseases. Xlife Sciences played a crucial role by advancing the project to clinical readiness. This development underscores their ability to identify and nurture high-value innovations within the life sciences sector.
DAZAmed signifies a new era in liver diagnostics, showcasing Xlife Sciences' model of connecting expertise and accelerating development to bring innovative ideas to the market.
R. H.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Xlife Sciences AG news